多层血流调节器支架治疗复杂主动脉病变的系统综述与荟萃分析
该系统综述与荟萃分析纳入39项研究(15项病例系列和24项病例报告),共429例患者,评估多层血流调节器(MFM)支架治疗复杂主动脉病变的安全性和有效性。汇总30天全因死亡率和动脉瘤相关死亡率分别为0.56%和0.00%,随访末血管通畅率99.12%,再干预率10.94%,内漏率10.70%。结论提示MFM支架在短期和中期是复杂主动脉病变的良好治疗选择,但缺乏长期随访数据。
要点
- 汇总30天全因死亡率为0.56%,动脉瘤相关死亡率为0.00%。
- 随访末血管通畅率为99.12%,再干预率10.94%,内漏率10.70%。
- 脊髓缺血和肾衰竭粗发生率分别为0.69%和1.8%,短期安全性较好。
核心结论
- MFM支架作为一线治疗且符合使用说明时,对复杂主动脉病变安全有效。
- 汇总30天全因和动脉瘤相关死亡率接近零,脊髓缺血和肾衰竭粗发生率低,提示短期和中期效果良好。
- 缺乏长期随访数据,需进一步研究器械长期有效性。
研究设计与样本
- 系统电子检索2008年12月至2020年5月发表的研究。
- 共纳入39项研究(15项病例系列和24项病例报告),涉及429例患者。
- 15项病例系列共404例患者,平均随访14.6个月。
- 共治疗436个病变,覆盖1521条主动脉分支。
主要发现
- 汇总30天全因死亡率为0.56%(95%CI 0.00%-2.54%),30天动脉瘤相关死亡率为0.00%(95%CI 0.00%-0.80%)。
- 1年随访动脉瘤相关死亡率为5.25%(95%CI 0.07%-14.91%)。
- 随访末血管通畅率为99.12%(95%CI 97.73%-99.93%)。
- 随访末再干预率为10.94%(95%CI 3.64%-20.67%),内漏率为10.70%(95%CI 4.45%-18.66%)。
- 脊髓缺血和肾衰竭粗发生率分别为0.69%和1.8%。
关键数值与推荐
- 8项病例系列报告了使用说明依从性,75%的手术在说明范围内进行。
- 12项病例系列中41%的患者既往接受过主动脉干预。
临床怎么用
- 对于复杂主动脉病变,可考虑将MFM支架作为一线治疗选择,但需严格遵循使用说明。
- 短期和中期结果良好,但应告知患者缺乏长期随访数据。
局限性
- 缺乏长期随访数据,无法评估器械长期有效性。
- 纳入研究以病例系列和病例报告为主,证据等级有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We evaluated the safety and efficacy of multilayer flow modulator (MFM) stents (Cardiatis, Isnes, Belgium) for the treatment of complex aortic lesions. METHODS: A systematic electronic research was conducted for studies reported from December 2008 to May 2020. Data extracted from 15 eligible case series (CS) were appropriately pooled and analyzed in a meta-analysis. The patient baseline characteristics were recorded, and 16 outcomes of interest were studied. The primary end points included 30-day all-cause and aneurysm-related mortality, aneurysm-related mortality at 1 year, vessel patency, and any endoleaks, ruptures, reinterventions, and aneurysm exclusion at the end of follow-up. RESULTS: A total of 39 studies (15 CS and 24 case reports), involving 429 patients, met the inclusion criteria. Overall, 436 lesions were treated, and 1521 aortic branches were covered by the multilayer stent. The mean follow-up for the 15 CS with 404 patients was 14.6 months. Compliance with the instructions for use was reported by eight CS, with 75% of the procedures performed within the instructions for use. However, 41% of the patients reported by 12 CS had undergone a previous aortic intervention. The pooled 30-day all-cause and 30-day aneurysm-related mortality rates were 0.56% (95% confidence interval [CI], 0.00%-2.54%) and 0.00% (95% CI, 0.00%-0.80%), respectively. The pooled aneurysm-related mortality at 1 year of follow-up was 5.25% (95% CI, 0.07%-14.91%). The pooled vessel patency at the end of follow-up was 99.12% (95% CI, 97.73%-99.93%). The pooled reintervention and endoleak rates at the end of follow-up were 10.94% (95% CI, 3.64%-20.67%) and 10.70% (95% CI, 4.45%-18.66%), respectively. The crude spinal cord ischemia and renal failure rates were 0.69% and 1.8%, respectively. CONCLUSIONS: The results from the present review and meta-analysis have indicated the safety and efficacy of MFM stents for treating challenging aortic pathologic lesions when used as first-line treatment and within the instructions for use. The almost zero pooled 30-day all-cause and aneurysm-related mortality rates combined with the low crude spinal cord ischemia and renal failure rates indicate the use of MFM stents is a good treatment option for complex aortic lesions in the short- and mid-term periods. The lack of long-term follow-up warrants further research concerning the efficacy of the device in the long term.
引用
- Bontinis V, Antonopoulos CN, Bontinis A, et al. A systematic review and meta-analysis of the streamliner multilayer flow modulator stent for treatment of complex aortic lesions. J Vasc Surg. 2021. PMID: 34019986. doi:10.1016/j.jvs.2021.03.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。